Abatacept for Graft Versus Host Disease Prophylaxis after Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research Trial
A study for patients with sickle cell disease receiving stem cell transplants
Sponsor: Bristol-Myers Squibb
Enrolling: Male and Female Patients
IRB Number: AAAQ2350
U.S. Govt. ID: NCT02867800
Contact: Brian Volonte: (212) 304-7806 / bv2272@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see whether or not the medicine, Abatacept, when given after hematopoietic stem cell transplantation (HSCT) is effective in treating GVHD in children and adolescents with sickle cell disease (SCD). We are also planning to gather additional information about the safety of treating sickle cell disease with a hematopoietic stem cell transplant as well as gather information about the medications used during transplant.
This study is closed
Investigator
Monica Bhatia, MD
Do You Qualify?
Are you between the ages of 3 and 20.99 years of age? Yes No
Has your child been diagnosed with sickle cell anemia? Yes No
Do you weight at least 10kg (22 pounds)? Yes No
Are you getting a bone marrow transplant? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Brian Volonte
bv2272@cumc.columbia.edu
(212) 304-7806
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE